Your browser doesn't support javascript.
loading
Describing IgA Myeloma: An Immunophenotypic and Molecular Approach.
Akgun, Yamac; Baykara, Yigit; Hacking, Sean M; Langlie, Jake; Huberman, Melissa Ann; Espejo, Andrea P; Chapman, Jennifer; Poveda, Julio.
Afiliação
  • Akgun Y; Department of Pathology and Laboratory Medicine, University of Miami and Jackson Health System, Miami, Florida.
  • Baykara Y; Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center, The Warren Alpert Medical School of Brown University, Providence, Rhode Island.
  • Hacking SM; Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School of Brown University; Department of Pathology and Laboratory Medicine, Donald and Barbara Zucker School of Medicine at Northwell.
  • Langlie J; University of Miami Miller School of Medicine, University of Miami and Jackson Health System, Miami, Florida.
  • Huberman MA; University of Miami Miller School of Medicine, University of Miami and Jackson Health System, Miami, Florida.
  • Espejo AP; Department of Hematology and Medical Oncology, University of Miami, Jackson Health System, Miami, Florida.
  • Chapman J; Department of Pathology and Laboratory Medicine, University of Miami and Jackson Health System, Miami, Florida.
  • Poveda J; Department of Pathology and Laboratory Medicine, University of Miami and Jackson Health System, Miami, Florida.
R I Med J (2013) ; 105(6): 41-45, 2022 08 01.
Article em En | MEDLINE | ID: mdl-35882000
ABSTRACT
Plasma cell myeloma (PCM) is defined as a clonal disease of terminally differentiated plasma cells that secrete immunoglobulin. The biologic underpinnings of IgA-type multiple myeloma's (IgAMM) aggressive nature, including its increased morbidity and mortality, have not been elucidated. We describe the clinical, phenotypic, and cytogenetic characteristics of IgA-MM. Flow-cytometry analysis was performed to phenotype clonal plasma cell populations, and interface with fluorescent in situ hybridization (iFISH) to exploit cytogenetics to determine risk stratification; 68.1% of cases were of intermediate or high risk. On flow cytometry, samples from our IgA-PCM cohort revealed less frequent CD56 expression when compared to samples with other PCM subtypes. Our study demonstrated lower frequency of CD56 expression (52.8%). We hypothesize that loss of CD56 may play a significant role in the aggressive behavior of IgA-PCM due to the loss of cell-to-cell adhesion resulting in a higher propensity for extramedullary presentation.
Assuntos
Palavras-chave
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Revista: R I Med J (2013) Ano de publicação: 2022 Tipo de documento: Article
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Revista: R I Med J (2013) Ano de publicação: 2022 Tipo de documento: Article
...